Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izalontamab brengitecan versus physician's choice chemotherapy in previously untreated advanced triple-negative or ER-low/HER2-negative breast cancer not eligible for PD-(L)1 therapy
MOH_2025-08-25_014296Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Bristol Myers Squibb. Started May 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2025-08-25_014296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-25_014296.